Objective: Metaplastic carcinoma of the breast is a rare malignant neoplasm comprised of ductal, squamous and/or mesenchymal elements in various proportions. Fine needle aspiration diagnosis of this entity is problematic because of its pathological heterogeneity. In this study, we have described the cytomorphological features of histologically confirmed metaplastic carcinomas and also discussed the diagnostic limitations along with a brief review of the literature. Study Design: In this observational study, the histology and cytology files of all cases identified as metaplastic carcinomas during the study period (2004–2009) were retrieved. The slides were reviewed for the presence of various elements. Results: Ten cases were identified as metaplastic carcinomas during the study period. All cases were diagnosed as malignant on cytology. Three cases showed presence of squamous carcinoma cells, 4 showed presence of atypical spindle cells, 2 showed presence of mesenchymal fragments and 1 showed presence of osteoclastic giant cells. Conclusion: The presence of biphasic tumor cells, atypical spindle cells admixed with poorly differentiated carcinoma cells, squamous carcinoma cells, osteoclastic giant cells and matrix may provide clues for the fine needle aspiration diagnosis of metaplastic carcinomas. However, cytological diagnosis may not be possible in all the cases because of selective sampling of various pathological elements.

Keywords:
Metaplastic carcinoma, Breast, Fine needle aspiration
1.
Tavassoli FA: Classification of metaplastic carcinomas of the breast. Pathol Annu 1992;27:89–119.
2.
Al Sayed AD, El Weshi AN, Tulbah AM, Rahal MM, Ezzat AA: Metaplastic carcinoma of the breast. Clinical presentation, treatment results and prognostic factors. Acta Oncol 2006;45:188–195.
3.
Stanford University: Metaplastic carcinoma of the breast. Surgical pathology criteria, 2009. http://surgpathcriteria.stanford.edu/breast/metacabr/ (accessed August 5, 2010).
4.
Wargotz ES, Deos PH, Norris HJ: Metaplastic carcinoma of the breast. 2. Spindle cell carcinoma. Hum Pathol 1989;20:732–740.
5.
Wargotz ES, Norris HJ: Metaplastic carcinoma of the breast. 3. Carcinosarcoma. Cancer 1989;64:1490–1499.
6.
Wargotz ES, Norris HJ: Metaplastic carcinoma of the breast. 1. Matrix-producing carcinoma. Hum Pathol 1989;20:628–635.
7.
Wargotz ES, Norris HJ: Metaplastic carcinoma of the breast. 4. Squamous cell carcinoma of ductal origin. Cancer 1990;21:1142–1150.
8.
Wargotz ES, Norris HJ: Metaplastic carcinoma of the breast. 5. Metaplastic carcinoma with osteoclastic giant cells. Hum Pathol 1990;21:1142–1150.
9.
Stanley MW, Tani EM, Skoog L: Metaplastic carcinoma of the breast: fine-needle aspiration cytology of seven cases. Diagn Cytopathol 1989;5:22–28.
10.
Ellis IO, Cornelisse CJ, Schnitt SJ, et al: Tumors of the Breast. Invasive Breast Carcinoma. Lyon, IARC Press, 2003.
11.
Huvos AG, Lucas JC, Foote FW: Metaplastic breast carcinoma: rare form of mammary cancer. NY State J Med 1973;73:1078–1082.
12.
Lui PCW, Tse GMK, Tan PH, et al: Fine-needle aspiration cytology of metaplastic carcinoma of the breast. J Clin Pathol 2007;60:529–533.
13.
Rosen PP: Carcinoma with Metaplasia, ed 3. Philadelphia, Lippincott, Williams and Wilkins, 2009.
14.
Park SP, Park S, Kim JH, et al: Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J 2010;51:864–869.
15.
Bilgen G, Memi A, Ustun EE, Zekioglu O, Ozdemir N: Metaplastic carcinoma of the breast: clinical, mammographic, and sonographic findings with histopathologic correlation. Am J Roentgenol 2002;178:1421–1425.
16.
Tse GM, Tan PH, Putti TC, Lui PCW, Chaiwun B, Law BKB: Metaplastic carcinoma of the breast: a clinicopathological review. J Clin Pathol 2006;59:1079–1083.
17.
Ribeiro-Silva A, Luzzatto F, Chang D, Zucoloto S: Limitations of fine-needle aspiration cytology to diagnose metaplastic carcinoma of the breast. Pathol Oncol Res 2001;7:298–300.
18.
Koker MM, Kleer CG: p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. Am J Surg Pathol 2004;28:1506–1512.
19.
Park HS, Park S, Kim JH, et al: Clinicopathologic features and outcomes of metaplastic breast carcinoma: comparison with invasive ductal carcinoma of the breast. Yonsei Med J 2010;51:864–869.
20.
Leibl S, Moinfar F: Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol 2005;58:700–704.
21.
Oberman HA: Metaplastic carcinoma of the breast. A clinicopathologic study of 29 patients. Am J Surg Pathol 1987;11:918–929.
22.
Kaufman MW, Marti JR, Gallager HS, Hoehn JL: Carcinoma of the breast with pseudosarcomatous metaplasia. Cancer 1984;54:1908–1917.
23.
Choa TC, Wang CS, Chen SC, Chen MF: Metaplastic carcinoma of the breast. J Surg Oncol 1999;71:220–225.
24.
Kline TS, Kline IK: Metaplastic carcinoma of the breast – a diagnosis by aspiration biopsy cytology: report of two cases and literature review. Diagn Cytopathol 1990;6:63–67.
25.
Nogueira M, Andre S, Mendonca E: Metaplastic carcinoma of the breast – fine needle aspiration (FNA) cytology findings. Cytopathology 1998;9:291–300.
26.
Gupta RK: Cytodiagnostic patterns of metaplastic breast carcinoma in aspiration samples: a study of 14 cases. Diagn Cytopathol 1999;20:10–12.
27.
Jayaram G, Sthaneshwar P: Fine-needle aspiration cytology of phyllodes tumors. Diagn Cytopathol 2002;26:222–227.
28.
Mardi K, Sharma J: Matrix-producing mammary carcinoma: a rare breast tumor. Indian J Pathol Microbiol 2008;51:263–264.
29.
Cook SS, Demay R: Adenocarcinoma of the breast with osseous metaplasia. Report of a case with needle aspiration cytology. Acta Cytol 1984;28:317–320.
30.
Stanford University: Breast carcinoma with osteoclast-like giant cells. Surgical pathology criteria, 2006. http://surgpathcriteria.stanford.edu/breast/osteoclastcabr/ (accessed February 9, 2011).
31.
Ng WK: Fine needle aspiration cytology of fibroadenoma with multinucleated stromal giant cells. A review of cases in a six-year period. Acta Cytol 2002;46:535–539.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.